📊 SBRA Key Takeaways
Is Sabra Health Care REIT, Inc. (SBRA) a Good Investment?
While Sabra demonstrates exceptional revenue growth (+117% YoY) and strong free cash flow generation ($348.6M, 45% margin), fundamental health is severely compromised by critically low interest coverage (0.3x), indicating operating income cannot cover interest obligations. Net income growth of only 0.1% despite massive revenue expansion signals poor acquisition quality or margin deterioration, compounded by weak capital returns (ROE 5.5%, ROA 2.8%).
Why Buy Sabra Health Care REIT, Inc. Stock? SBRA Key Strengths
- Exceptional free cash flow generation of $348.6M with 45% FCF margin
- Strong revenue growth of 117% year-over-year demonstrates operational scale
- Moderate leverage with 0.90x debt-to-equity ratio, manageable for REIT structure
SBRA Stock Risks: Sabra Health Care REIT, Inc. Investment Risks
- Critical interest coverage of 0.3x indicates operating income insufficient to cover debt service; unsustainable without strong NOI or working capital reliance
- Poor growth quality: net income grew only 0.1% despite 117% revenue growth, suggesting acquisitions at lower margins or significant operating headwinds
- Weak capital efficiency with ROE of 5.5% and ROA of 2.8% indicate poor returns on shareholder and asset base
Key Metrics to Watch
- Interest coverage ratio trajectory and debt service capability in next quarters
- Operating margin improvement and profitability per property to assess acquisition integration
- Funds From Operations (FFO) and Net Operating Income (NOI) as REIT-specific cash generation metrics
Sabra Health Care REIT, Inc. (SBRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 45.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
SBRA Profit Margin, ROE & Profitability Analysis
SBRA vs Real Estate Sector: How Sabra Health Care REIT, Inc. Compares
How Sabra Health Care REIT, Inc. compares to Real Estate sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sabra Health Care REIT, Inc. Stock Overvalued? SBRA Valuation Analysis 2026
Based on fundamental analysis, Sabra Health Care REIT, Inc. has mixed fundamental signals relative to the Real Estate sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sabra Health Care REIT, Inc. Balance Sheet: SBRA Debt, Cash & Liquidity
SBRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sabra Health Care REIT, Inc.'s revenue has grown significantly by 129% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.06 reflects profitable operations.
SBRA Revenue Growth, EPS Growth & YoY Performance
SBRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $73.7M | $22.5M | $0.09 |
| Q2 2025 | $67.9M | $24.0M | $0.10 |
| Q1 2025 | $66.0M | $26.3M | $0.11 |
| Q3 2024 | $59.7M | -$3.4M | $-0.01 |
| Q2 2024 | $58.4M | $11.7M | $0.05 |
| Q1 2024 | $56.7M | -$9.5M | $-0.04 |
| Q3 2023 | $47.6M | -$3.4M | $-0.01 |
| Q2 2023 | $44.1M | $11.7M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sabra Health Care REIT, Inc. Dividends, Buybacks & Capital Allocation
SBRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sabra Health Care REIT, Inc. (CIK: 0001492298)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 26, 2026 | 4 | xslF345X06/wk-form4_1774574755.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772566022.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772565995.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772565965.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772565939.xml | View → |
❓ Frequently Asked Questions about SBRA
What is the AI rating for SBRA?
Sabra Health Care REIT, Inc. (SBRA) has an AI rating of SELL with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SBRA's key strengths?
Claude: Exceptional free cash flow generation of $348.6M with 45% FCF margin. Strong revenue growth of 117% year-over-year demonstrates operational scale.
What are the risks of investing in SBRA?
Claude: Critical interest coverage of 0.3x indicates operating income insufficient to cover debt service; unsustainable without strong NOI or working capital reliance. Poor growth quality: net income grew only 0.1% despite 117% revenue growth, suggesting acquisitions at lower margins or significant operating headwinds.
What is SBRA's revenue and growth?
Sabra Health Care REIT, Inc. reported revenue of $774.6M.
Does SBRA pay dividends?
Sabra Health Care REIT, Inc. pays dividends, with $289.5M distributed to shareholders in the trailing twelve months.
Where can I find SBRA SEC filings?
Official SEC filings for Sabra Health Care REIT, Inc. (CIK: 0001492298) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SBRA's EPS?
Sabra Health Care REIT, Inc. has a diluted EPS of $0.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SBRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sabra Health Care REIT, Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SBRA stock overvalued or undervalued?
Valuation metrics for SBRA: ROE of 5.5% (sector avg: 8%), net margin of 20.1% (sector avg: 20%). Compare these metrics with sector averages to assess valuation.
Should I buy SBRA stock in 2026?
Our dual AI analysis gives Sabra Health Care REIT, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SBRA's free cash flow?
Sabra Health Care REIT, Inc.'s operating cash flow is $348.6M, with capital expenditures of N/A. FCF margin is 45.0%.
How does SBRA compare to other Real Estate stocks?
Vs Real Estate sector averages: Net margin 20.1% (avg: 20%), ROE 5.5% (avg: 8%), current ratio N/A (avg: 1.5).